New obesity drug ARO-ALK7 enters human trials – could it help with diabetes too?

NCT ID NCT06937203

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 24 times

Summary

This early-stage study tests a new drug called ARO-ALK7 in 138 adults with obesity, some of whom also have type 2 diabetes. The goal is to check if the drug is safe and how it affects weight and blood sugar. Participants receive either the drug or a placebo, and some may also take a standard diabetes medication (tirzepatide) to see if combining them works better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site 1

    RECRUITING

    Auckland, 1010, New Zealand

    Contact

  • Research Site 2

    RECRUITING

    Christchurch, 8011, New Zealand

    Contact

  • Research Site 3

    RECRUITING

    Takapuna, Auckland, 0622, New Zealand

    Contact

  • Research Site 4

    RECRUITING

    Rotorua, 3010, New Zealand

    Contact

  • Research Site 5

    RECRUITING

    Grafton, Auckland, 1010, New Zealand

    Contact

  • Research Site 6

    RECRUITING

    Papatoetoe, Auckland, 2025, New Zealand

    Contact

  • Research Site 7

    NOT_YET_RECRUITING

    Nedlands, Western Australia, 6009, Australia

    Contact

  • Research Site 8

    RECRUITING

    Morayfield, QLC, 4506, Australia

    Contact

Conditions

Explore the condition pages connected to this study.